Hi Afford,
I'm sorry for any confusion, I received a monoclonal antibody vaccine (MAB). The vaccine is similar to the DCvax, in that it is manufactured from tumor tissue surgically removed from the patient (autologous). My tissue was removed at Kaiser and my parents drove the tissue over in a little igloo playmate on blue ice (the tissue had been prepared per the clinical trial protocol specifications by the surgeon). They handed it over to Stanford's nurse coordinator and they cryofroze it for the use of manufacturing my personalized vaccine. One of the differences is I had a blood related cancer non-hodgkins lymphoma (NHL) and they were only targeting 1 antigen. (As you know DCVax targets many antigens) They had to locate that antigen first, (they -the Dr.'s were not expecting to find it on my type of cancer cells) they found it their first try, I was told. They then fused a foreign protein from a keyhole limpid to the antigen, cloned it, (this process took up to 6 months) then reintroduced the cells in a vaccine form using some kind of adjuvant. My body saw the antigen as foreign after receiving the vaccine over a period of 6 months and began producing antibodies to fight it off. No more cancer.
Similarities of the 2 trials
1. Patients are Treatment Naive
2. Autologous vaccine - Personalized Vaccine
3. Patient is cancer free prior to 1st vaccinations
4. Administration of the vaccine is nearly identical, 2 shots, one in each arm and spaced in a tiered timeline.
5. Goal - to create an immune response
Also, as a patient in a clinical trial, at the time I was not allowed to discuss any of the specifics of my treatment with anyone other than my Drs and family, during the trial. This was a Phase II with no placebo arm. (That came later.) I believe anyone in the Phase 3 DCVax-L are probably required to not disclose similar information. Even with my friend, I have felt compelled at times to not share his info, because of a possible backlash. But since Dr. Bosch has shared, I suppose it won't matter now.
I hope I was able to clear up any confusion.
News 
Market Data 
Discover 
